Study S003288

A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate Efficacy, Safety, and Tolerability of HM15275 for 36 Weeks in Subjects With Type 2 Diabetes Mellitus

ClinicalTrials.gov record

Registration

Registration: NCT07527650
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: TRIPLE
Status: RECRUITING
Enrollment: 180
Start: 2026-05-18
Primary completion: 2027-10
Lead sponsor: Hanmi Pharmaceutical Company Limited
Conditions: Type 2 Diabetes Mellitus; T2DM
Interventions: DRUG:HM15275; DRUG:Placebo of HM15275
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Change in Glycated Hemoglobin (HbA1c) [Up to 41 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.